Posted by on June 23, 2022 8:50 am
Categories: Breaking News News Newsmax

A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic.

Originally appeared on Newsmax Read More

Leave a Reply

Your email address will not be published.